RARE DISEASERESEARCH ATLAS

ORPHA:75564

Acquired idiopathic sideroblastic anemia

medium confidenceDisorder

Also known as: AISA · Primary acquired sideroblastic anemia · RARS · Refractory anemia with ringed sideroblasts

Publications

5,175

90.5th percentile

Trials

19

Interventional, condition-specific

Researchers

1,518

Distinct authors in sample

Gene link

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare myelodysplastic syndrome (MDS) characterized by ineffective hemopoiesis affecting one or more blood cell lineages (myeloid, erythroid or megakaryocytic) leading to peripheral blood cytopenias and an increased risk of developing leukaemia.

How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (15)

MDS with ring sideroblasts · MDS-RS · Pure sideroblastic Anaemia · Pure sideroblastic Anemia · acquired idiopathic sideroblastic anaemia · acquired idiopathic sideroblastic anemia · myelodysplastic syndrome with Ring sideroblasts · primary acquired sideroblastic anaemia · primary acquired sideroblastic anemia · refractory Anaemia with Ring sideroblasts · refractory Anaemia with ringed sideroblasts · refractory Anemia with Ring sideroblasts · refractory Anemia with ringed sideroblasts · refractory anaemia with ringed sideroblasts · refractory anemia with ringed sideroblasts

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    5,175 matched papers (1,922 in last 10 years) Source

  3. Phenotype characterisedPresent

    28 HPO annotations (e.g. Normochromic anemia; Normocytic anemia; Abnormal fingernail morphology) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    19 matched on ClinicalTrials.gov (1 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

28

Associated phenotypes · MONDO:0019157

  • Normochromic anemia
  • Normocytic anemia
  • Abnormal fingernail morphology
  • Hypochromic anemia
  • Increased total leukocyte count

Showing 5 of 28 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

5,175

5,175 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

5,175 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

1,922 in the last 10 years · medium confidence · 90.5th percentile (publications denominator)

Phrase hits: 5,175 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,518

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Hellström-Lindberg E8 papers · 2026

    Karolinska Institutet, Stockholm, Sweden.

    Papers in Europe PMC
  2. 02
    Hou HA6 papers · 2026

    Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. hsinanhou@ntu.edu.tw.

    Papers in Europe PMC
  3. 03
    Park S6 papers · 2026

    Department of Haematology CHU Grenoble Alpes Grenoble France.

    Papers in Europe PMC
  4. 04
    Patnaik MM6 papers · 2022

    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

    Papers in Europe PMC
  5. 05
    Tefferi A6 papers · 2022

    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

    Papers in Europe PMC
  6. 06
    Tien HF6 papers · 2026

    Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

    Papers in Europe PMC
  7. 07
    Barbosa I5 papers · 2025

    Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden.

    Papers in Europe PMC
  8. 08
    Chou WC5 papers · 2026

    Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

    Papers in Europe PMC
  9. 09
    Creignou M5 papers · 2026

    Phase 1 unit, Center for Clinical Cancer Studies, Karolinska University Hospital, Stockholm, Sweden.

    Papers in Europe PMC
  10. 10
    Li X5 papers · 2026

    State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, People's Republic of China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

19

interventional trials for this specific condition

19 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 1 trial are registered for sideroblastic anemia, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026

19 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 94.6th percentile).

medium confidence · 94.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

19 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: sideroblastic anemia

1

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

None of the matched observational studies is currently listed as recruiting.

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Acquired idiopathic sideroblastic anemia — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Acquired idiopathic sideroblastic anemia" OR "Primary acquired sideroblastic anemia" OR "Refractory anemia with ringed sideroblasts" OR "MDS with ring sideroblasts" OR "MDS-RS" OR "Pure sideroblastic Anaemia" OR "Pure sideroblastic Anemia" OR "acquired idiopathic sideroblastic anaemia" OR "myelodysplastic syndrome with Ring sideroblasts" OR "primary acquired sideroblastic anaemia" OR "refractory Anaemia with Ring sideroblasts" OR "refractory Anaemia with ringed sideroblasts" OR "refractory Anemia with Ring sideroblasts"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Acquired idiopathic sideroblastic anemia" OR "Primary acquired sideroblastic anemia" OR "Refractory anemia with ringed sideroblasts" OR "MDS with ring sideroblasts" OR "MDS-RS" OR "Pure sideroblastic Anaemia" OR "Pure sideroblastic Anemia" OR "acquired idiopathic sideroblastic anaemia" OR "myelodysplastic syndrome with Ring sideroblasts" OR "primary acquired sideroblastic anaemia" OR "refractory Anaemia with Ring sideroblasts" OR "refractory Anaemia with ringed sideroblasts" OR "refractory Anemia with Ring sideroblasts"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 19 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"sideroblastic anemia"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: AISA; RARS

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 2 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T01:50:21.215Z